CAR-T for multiple myeloma: when to consider it and what to compare

Why CAR-T is used in myeloma

Several myeloma CAR-T products target BCMA, a protein on plasma cells. The patient's T cells are collected and modified to recognize that target, then returned after preparatory treatment. Some patients experience deep responses and a period without regular antimyeloma drug dosing, while follow-up and supportive care continue.

CAR-T assessment is most useful when it starts with your treatment history. Bring the names of the combinations you received, how well each worked and why it stopped. A drug stopped for intolerance may leave different options from one stopped because the myeloma progressed.

Sources and references: [1] [2]

Treatment-line requirements differ between products

In the United States, ciltacabtagene autoleucel, or Carvykti, is approved for adults with relapsed or refractory myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, with disease refractory to lenalidomide. Idecabtagene vicleucel, or Abecma, has a different requirement: at least two prior lines including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody.

These examples show why a specific product review matters. For care in Shanghai, the team needs to check the current Chinese indication and the hospital's treatment arrangements. Count complete treatment lines with your hematologist, including maintenance and any changes made for toxicity.

Sources and references: [3] [4]

Discuss the actual Chinese treatment option

China has approved BCMA-directed CAR-T products for myeloma. For example, the NMPA's 2023 conditional approval of equecabtagene autoleucel covered adults whose relapsed or refractory myeloma progressed after at least three prior lines including a proteasome inhibitor and an immunomodulatory agent.

Ask the receiving center which product it is considering and request the current indication, assessment requirements and expected timing. This turns a broad request for CAR-T into a concrete decision. It also helps you understand whether the proposed route is an approved treatment or a clinical trial.

Sources and references: [5]

The pace of relapse affects the timing

Some relapses show a gradual rise in a myeloma marker. Others cause rapidly worsening kidney function, bone problems, anemia or disease outside the marrow. The team needs to assess how urgently treatment is required and whether the disease can be controlled while cells are manufactured.

If bridging treatment is proposed, ask what it is intended to achieve and how response will be checked before infusion. Discuss a backup option if the disease changes during preparation. Bringing recent laboratory trends, rather than only the latest result, helps the specialist judge the pace.

Sources and references: [1] [4]

Compare CAR-T with the treatments available to you

Alternatives may include combinations of anti-CD38 antibodies, proteasome inhibitors, immunomodulatory medicines, steroids, bispecific antibodies or other agents. Their relevance depends on what the myeloma remains sensitive to, prior side effects and local availability. A stem cell transplant may be discussed in selected circumstances.

Bispecific antibodies can be supplied without collecting and manufacturing an individual cell product. They have their own dosing and monitoring requirements, often with ongoing treatment. Ask how quickly each option can start, what infection protection it needs and how it might affect the next treatment if relapse occurs.

Sources and references: [1] [6]

Look closely at the safety and recovery plan

CAR-T can cause CRS, neurological effects, infection and prolonged low blood counts. Antibody levels may also fall. The team will explain which symptoms need urgent attention and how it will monitor and support recovery. Product-specific issues matter; Carvykti also carries a warning about potentially severe delayed bowel inflammation.

Tell the team about recurrent infections, nerve symptoms, heart or kidney problems and the amount of help you need day to day. These details influence preparation and follow-up. Ask who will manage ongoing blood tests and infection prevention after you leave the treatment center.

Sources and references: [4] [7]

Plan how response will be measured

Myeloma response is assessed using the tests appropriate to your disease, such as blood or urine markers, marrow examination and imaging. A response can deepen over time. Ask when each assessment is planned and which change would lead the team to investigate further.

If minimal residual disease testing is discussed, ask what sample and method will be used and how the result fits the broader picture. A deep response still needs scheduled follow-up. You should leave the center knowing who tracks the markers and how results will reach the CAR-T team.

Sources and references: [1]

Organize a myeloma review in Shanghai

EastMedGo can help prepare a treatment timeline and coordinate a CAR-T assessment request in Shanghai. Ruijin Hospital is one local hematology resource; matching a center requires checking the specific treatment and case requirements.

Through our contact page, share the diagnosis, prior regimens, transplant history and the latest status of the disease. We can help clarify which marrow, imaging and laboratory reports the receiving team needs, then organize appointment logistics and questions about the local stay. The aim is a comparison you can use before committing to a treatment trip.

Sources and references: [8]

Common questions